Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : 1529-1543

Bentham Science Publishers

Access to resources Recommend Favorite

Is uPAR the Centre of a Sensing System Involved in the Regulation of Inflammation?

By  

Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, Vol. 2, Iss. 3, 2003-09 ,pp. : 237-259

Bentham Science Publishers

Access to resources Recommend Favorite

Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications

By  

Current Cancer Drug Targets, Vol. 5, Iss. 7, 2005-11 ,pp. : 471-488

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy

By Frankenne F.   Noel A.   Bajou K.   Sounni N.   Goffin F.   Masson V.   Munaut C.   Remacle A.   Foidart J.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 3, 1999-09 ,pp. : 469-481

Informa Healthcare

Access to resources Recommend Favorite

uPA-anthrax toxin: promising antitumour activity

By  

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite